What changed for Leukaemia
A plain English summary of what recently moved in the public data Voxsanity tracks for Leukaemia. Updated from government registries. Not medical advice.
How to read these changes: every figure on this page is the difference between two snapshots of what Voxsanity had tracked on each date. Voxsanity only began taking daily snapshots in July 2026 and is still ingesting the public registries, so a rise here is mostly our own coverage expanding rather than new research appearing. Read it as our tracked coverage growing, not as a claim about real-world research changing this fast: it overstates how much actually changed.
Comparing the two most recent snapshots, 27 July 2026 and 28 July 2026.
- Trials recruiting at Australian sites 34 to 40 (+6)
- Trials recruiting worldwide 561 to 612 (+51)
- Late-stage (Phase 3) trials 51 to 56 (+5)
- Trials on record 3,227 to 3,456 (+229)
Newly subsidised on the PBS
No medicines were newly subsidised on the PBS for Leukaemia in July 2026. Voxsanity tracks 23 PBS-subsidised medicines for this condition; none of them was listed for the first time this month.
Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.
Past updates
Tracking began in July 2026. Month on month changes will appear here once a second month of data has been recorded. Until then, the comparison above shows the most recent movement.
Recent trend
Weekly, most recent weeks (fills out to a monthly trend as history grows).
Recent trial results
The 30 most recent of 176 trials tracked for Leukaemia that have reported results to a public registry.
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
-
NCT03573024 · results posted 11 June 2026
According to the results reported on ClinicalTrials.gov, this trial enrolled 36 adults who received a combination of two medicines — azacitidine and venetoclax. All 36 participants completed the study. The trial was measuring how many people responded to the treatment combination, using a set of response categories defined by a group called the European LeukemiaNet (which includes things like complete remission — meaning no signs of leukaemia were detectable in standard tests). It also measured how many people achieved what is called "MRD-negative" status, which means that even very sensitive...
-
NCT04161885 · results posted 4 June 2026
According to the results reported on ClinicalTrials.gov, this trial (NCT04161885) was conducted in two parts. Part 1 involved 35 people and was designed to look at whether certain side effects — called dose-limiting toxicities — occurred when participants received a combination of two medicines, venetoclax and azacitidine, at different dosing schedules. Part 2 was a larger, randomised phase involving 430 people (216 in the best supportive care group and 214 in the venetoclax plus azacitidine group), and its main goal was to measure overall survival — that is, how long participants lived from t...
-
NCT05583552 · results posted 12 May 2026
According to the results reported on ClinicalTrials.gov, this trial (NCT05583552) looked at a drug called imetelstat sodium in people with certain blood cancers (MDS – a bone marrow condition – and AML, a type of leukaemia). A total of 46 people took part, split evenly into two groups of 23: one group received the drug once per treatment cycle, and the other received it twice per cycle. The main thing the trial was measuring was whether participants' blood counts showed a recognised response to treatment, using standard international criteria. A secondary measure tracked how many people experi...
-
NCT03150004 · results posted 30 March 2026
According to the results reported on ClinicalTrials.gov, this trial (NCT03150004) enrolled 53 people in total — 40 in the CLAG-M treatment group and 13 in the CLLDAC treatment group. All participants who started the trial were recorded as having completed it. The trial was measuring whether patients achieved a very deep type of remission (called "MRD complete remission," meaning no detectable signs of disease could be found using sensitive tests), as well as how long participants lived overall and how long they remained in remission without their disease coming back. The reported data shows t...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05115630 · results posted 19 December 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 24 participants who were undergoing a stem cell transplant (a procedure where healthy blood-forming cells from a donor are given to a patient). The trial was looking at a treatment approach that combined an infusion of specialised immune cells called NK (natural killer) cells with a preparatory regimen of three medicines/treatments — fludarabine, melphalan, and low-dose radiation (TBI) — given before the transplant. Of the 24 people who started, 21 completed the study and 3 did not. The reported data shows that the m...
-
NCT04266301 · results posted 12 December 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04266301) enrolled 530 people in total — 265 in each group. One group received a medicine called sabatolimab combined with azacitidine, while the other group received a placebo (an inactive dummy treatment) combined with azacitidine. The main thing the trial was measuring was overall survival — that is, how long participants lived from the time they were enrolled in the study until death from any cause. The trial also measured several secondary things, including how long it took for fatigue to get noticeably worse, how man...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04150029 · results posted 17 November 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04150029) enrolled 90 people in total — 5 in a lower-dose group receiving MBG453 400 mg combined with two other medicines (venetoclax and azacitidine), and 85 in a higher-dose group receiving MBG453 800 mg with the same two medicines. The trial was looking at a combination treatment for a blood cancer condition and measured two main things: first, how many participants in the lower-dose "safety check" phase experienced certain serious side effects during the early part of the study (called dose-limiting toxicities); and se...
-
NCT03263936 · results posted 16 October 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 37 people in total across three groups, each receiving a different dose of a drug called decitabine combined with a chemotherapy regimen known as FLAG (which includes the drugs fludarabine, high-dose cytarabine, and G-CSF, plus vorinostat). The main thing the trial was measuring was how much decitabine could be given alongside this combination — specifically, by looking at whether participants experienced what researchers call a "dose-limiting toxicity" (a serious side effect severe enough to prevent increasing the do...
-
NCT05168202 · results posted 25 September 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT05168202) enrolled 56 people in total across seven treatment groups (called Part A, Treatments 1 through 7), with group sizes ranging from 5 to 10 participants. The trial was an early-phase study, meaning its main focus was on closely monitoring participants for any unwanted medical events rather than testing whether the treatment produced a particular health benefit. Notably, the reported data shows that zero participants were recorded as having "completed" the study in any group — the reasons for this were not detailed i...
-
NCT02752035 · results posted 12 September 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT02752035) looked at treatments for a type of blood cancer called acute myeloid leukaemia (AML). It tested a drug called gilteritinib, either on its own or combined with another drug called azacitidine (AZA), compared to azacitidine alone. A total of 15 people took part in an initial safety testing phase, and then 168 people were randomly assigned to one of three groups: gilteritinib combined with AZA (89 people), AZA alone (57 people), or gilteritinib alone (22 people). The main thing the trial was measuring was overall su...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04102020 · results posted 20 August 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04102020) enrolled 112 people across five groups. The trial was testing two different drug combinations in people with a blood cancer condition. One part of the trial (Part 1) looked at the drug venetoclax combined with an injected form of azacitidine at three different doses — 20, 36, or 50 mg/m² — with 23, 23, and 20 participants respectively. Another part (Part 3) tested venetoclax combined with a tablet form of azacitidine (called CC-486) at two dose levels — 200 mg or 300 mg — with 30 and 16 participants respectively....
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02719574 · results posted 26 June 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT02719574) tested a drug called FT-2102 (also known as olutasidenib) in people with certain blood cancers, including acute myeloid leukaemia (AML) and a condition called myelodysplastic syndrome, that carried a specific gene change called an IDH1 mutation. The trial ran in two main stages: a Phase 1 stage to explore different doses and combinations (either FT-2102 alone or paired with other medicines called azacitidine or cytarabine), and a Phase 2 stage testing several groups of patients. In total, across all groups and st...
Read the full trial page · View reported results on ClinicalTrials.gov ↗
-
NCT02521493 · results posted 13 June 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 280 people in total across three groups: 114 in the "Standard Risk" group (Arm A), 44 in the "High Risk" group (Arm B), and 122 in a "No Risk Stratification" group. The trial was measuring how well participants fared over time after treatment for what appears to be a blood cancer, specifically looking at something called "event-free survival" — that is, how many people went for at least two years without their illness coming back, failing to respond to treatment, developing a second cancer, or dying. The reported dat...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03286114 · results posted 11 May 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT03286114) enrolled 16 people, all of whom received a drug called pembrolizumab. The trial was looking at a type of blood cancer (leukaemia), and its main goals were to find out how many participants showed a "clinical benefit" — meaning their disease either stabilised or reduced — and how many had a measurable response to treatment. The trial also tracked serious immune-related side effects, including a condition called Graft Versus Host Disease (GvHD), where the immune system attacks the body's own tissues. The reported...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04285567 · results posted 17 April 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04285567) enrolled 80 people in one group receiving a combination called VEN+G (venetoclax plus obinutuzumab) and 86 people in a comparison group receiving either FCR or BR (established chemotherapy-based regimens). The trial was looking at a type of blood cancer called chronic lymphocytic leukaemia (CLL). The main thing being measured was something called "minimal residual disease" (MRD) negativity in the blood — in plain terms, this means whether very sensitive testing could detect any remaining cancer cells after treatm...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05079230 · results posted 4 April 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT05079230) enrolled 378 adults with acute myeloid leukaemia (a type of blood cancer). Participants were randomly assigned to one of two groups of 189 people each: one group received a combination of three medicines — magrolimab, venetoclax, and azacitidine — while the other group received the same two medicines (venetoclax and azacitidine) plus a placebo (a dummy version of magrolimab). The trial was primarily measuring how long participants lived overall, and also tracked several secondary measures including how many peopl...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03953898 · results posted 30 March 2025
According to the results reported on ClinicalTrials.gov, this trial looked at a drug called olaparib in people with certain blood cancers (myelodysplastic syndrome or acute myeloid leukaemia). Fourteen people were enrolled, and 12 of those went on to start treatment. The trial was measuring how many participants had their cancer respond to the treatment over up to six cycles, as well as how long people lived without their disease getting worse, how long they survived overall, and how many experienced unwanted side effects. The reported data shows that, out of the 12 participants who started t...
-
NCT04284787 · results posted 13 March 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04284787) enrolled 60 people in total — 31 in one group receiving two drugs (azacitidine and venetoclax, sometimes called AZA and VEN), and 29 in a second group receiving those same two drugs plus a third drug called pembrolizumab. The trial was mainly measuring how many participants achieved a specific type of deep remission — known as "MRD-negative complete remission" — which broadly means that very sensitive testing could no longer detect signs of the disease in the blood or bone marrow after treatment. None of the part...
-
NCT04971226 · results posted 10 March 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04971226) enrolled 405 people in total across four groups. Participants were split based on which type of leukaemia medicine they had previously taken, and then randomly assigned to receive either asciminib or a medicine chosen by their doctor (called an "investigator selected TKI" — a type of targeted cancer tablet). The trial's main goal was to measure how many people in each group achieved something called a "Major Molecular Response" (MMR) by week 48. MMR means that the amount of a specific leukaemia-related signal det...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04666038 · results posted 7 March 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04666038) enrolled 119 participants in each of two groups — 238 people in total — with a type of blood cancer called chronic lymphocytic leukaemia or small lymphocytic lymphoma. One group received a medicine called pirtobrutinib, while the other received one of two established combination treatments (idelalisib plus rituximab, or bendamustine plus rituximab). The trial's main goal was to measure how long participants went without their disease getting worse or dying — a timeframe known as "progression-free survival." The...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04745676 · results posted 10 February 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04745676) looked at whether a telehealth-based advance care planning program — helping people plan ahead for future medical decisions — was practical to run and easy to use. A total of 36 people took part across three groups: 20 patients (of whom 21 were approached and agreed to join), 6 caregivers, and 10 clinicians. The trial measured how many people stayed in the study, how many signed up, and how easy the telehealth platform was to use. It also tracked changes in participants' anxiety, depression, and distress scores b...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05447663 · results posted 14 January 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT05447663) was testing a drug called siremadlin (also known as HDM201) in people with acute myeloid leukaemia (a type of blood cancer) who had undergone a stem cell transplant. The trial was designed in two parts: the first part looked at siremadlin on its own to find a tolerable dose, and the second part was planned to test siremadlin combined with a treatment called donor lymphocyte infusion (a transfusion of immune cells from the original stem cell donor). Eight participants were enrolled in the first part of the trial,...
-
NCT02890329 · results posted 7 January 2025
According to the results reported on ClinicalTrials.gov, this trial looked at a combination of two drugs — decitabine and ipilimumab — given to people with certain blood cancers (acute myeloid leukaemia or myelodysplastic syndrome). The trial had two main groups: people who had already received a bone marrow transplant (Arm A), and people who had not (Arm B). Across three rounds of testing at increasing doses, a total of 54 people took part. The trial was primarily trying to find the highest dose of ipilimumab that could be given alongside decitabine without too many serious dose-related side...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02488408 · results posted 19 December 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT02488408) tested a drug called bemcentinib (also known as BGB324) in people with certain blood cancers, specifically acute myeloid leukaemia (AML) and myelodysplastic syndrome (MDS). The trial ran in two stages. In the first stage (Part A), 36 people took part across five groups, each receiving different doses of bemcentinib on its own, to find out what the highest tolerable dose was. In the second stage (Part B), 86 people took part across five groups, receiving bemcentinib either alone or combined with other medicines (c...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02397720 · results posted 4 November 2024
According to the results reported on ClinicalTrials.gov, this trial enrolled 156 participants across six treatment groups, though one group (Arm 3B) did not end up including any participants. The trial tested different combinations of medicines — azacitidine paired with nivolumab alone, or with the addition of either ipilimumab or venetoclax — in people with a blood cancer. The trial was looking at things like the highest dose that could be given without too many serious side effects in the early "lead-in" phases (6 participants each), as well as how many people showed a response to treatment,...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04277442 · results posted 22 October 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT04277442) enrolled only one participant, who was assigned to receive a combination of three medicines: nivolumab, decitabine, and venetoclax. The trial was designed to test whether this combination was feasible — meaning whether patients could get through three full rounds ("cycles") of treatment — and to track any unwanted side effects. The original plan had been to enrol 13 people, with the goal considered met if at least 10 of them completed three cycles. The reported data shows that the single participant who started...
-
NCT03541369 · results posted 10 October 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT03541369) tested a drug called emirodatamab — given alone or in combination with another medicine called etanercept — in a total of 74 people across 18 different dosing groups. Participants were assigned to receive different dose levels or combinations, and the trial was primarily a "first-in-human" study, meaning it was an early-stage trial designed to explore how the drug behaves in the body at various dose levels and to track any serious medical events that occurred within a defined window after dosing. The trial also m...
-
NCT01838395 · results posted 19 September 2024
According to the results reported on ClinicalTrials.gov, this trial enrolled 42 people in total across six dose groups. Participants received a combination of two treatments: BL-8040 (given as an injection under the skin) and a chemotherapy drug called Ara-C. The trial tested increasing doses of BL-8040 — starting at 0.5 mg per kilogram of body weight and going up to 2.0 mg per kilogram — to measure how well the combination was tolerated and to track what happened in participants' blood and bone marrow. Most participants completed the study, with three people across all groups not finishing....
-
NCT03735875 · results posted 19 September 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT03735875) looked at a combination of two medicines — venetoclax and quizartinib — in people with a type of blood cancer (leukaemia). The trial had two planned stages: a Phase I (dose-finding) stage and a Phase II stage. The reported data shows that 8 participants were enrolled into the Phase I dose-finding group, and all 8 completed that stage. No participants were enrolled into the Phase II group, so all results below relate only to the Phase I stage. The reported data shows that the highest dose of venetoclax that parti...
-
NCT02997202 · results posted 19 September 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT02997202) enrolled 178 participants in the gilteritinib group and 178 in the placebo group — 356 people in total. The trial was looking at people who had received a stem cell transplant for a type of blood cancer called acute myeloid leukaemia (AML) that carried a specific gene change known as FLT3. The main thing the trial was measuring was how long participants went without their disease coming back (called "relapse-free survival"). It also tracked a number of other things, including how long participants lived overall,...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
See all 176 reported results for Leukaemia
These are the results as reported to the registry, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
What is coming
AI generated pipeline summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to NIH funding data, leukaemia receives a very large amount of public research investment from the United States government, and that level of support has remained broadly steady over time. For patients, this signals that leukaemia is a well-established research priority with a sustained scientific community working on it. Consistent funding at this scale generally supports a wide range...
Not medical advice. Voxsanity republishes public government health data in plain English. These figures describe research and registry activity, not the suitability of any treatment for any person. Trial status can change; always verify current status directly with the trial site and confirm Australian availability with your doctor.